Drug Trial Radar · NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Dec 20, 2022
Primary completion
Aug 2026
Study completion Aug 2027
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Conditions
- Solid Tumors
- ER+ Breast Cancer
- Triple Negative Breast Cancer, TNBC
- ARID1A Gene Mutation
- Small Cell Lung Cancer, SCLC
Interventions
JAB-2485 (Aurora A inhibitor)Drug
Administered orally
JAB-2485 (Aurora A inhibitor)Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)Time frame: First 21 days of Cycle 1
- Dose Escalation phase: Number of participants with adverse events (AEs)Time frame: Up to 3 years
- Dose Expansion phase: Objective Response Rate (ORR)Time frame: Up to 3 years from baseline to RECIST confirmed Progressive Disease (PD)
- Dose Expansion phase: Duration of Response (DOR)Time frame: Up to 3 years
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Henry Ford Health System
Detroit, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.